The conundrum of abundance: challenges of having too many biosimilars [0.03%]
从丰富性中寻找答案——生物类似药“太多”了吗？
Ashish Sharma,Carl D Regillo,Luke Nicholson et al.
Ashish Sharma et al.
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study [0.03%]
抗TNF治疗失败后的慢性活动性中重度溃疡性结肠炎患者二线治疗策略：一项回顾性的多中心队列研究
Bernadett Farkas,Jimmy K Limdi,Péter Bacsur et al.
Bernadett Farkas et al.
Background: Many ulcerative colitis (UC) patients require the use of second-line agents after the failure of anti-TNF therapy. Research design and methods...
Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy? [0.03%]
复发性铂类耐药型卵巢癌的条件复制腺病毒溶瘤免疫治疗展望
Santeri Artturi Pakola,James Hugo Armstrong Clubb,Joao Manuel Santos et al.
Santeri Artturi Pakola et al.
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis [0.03%]
关于将抗CD20单克隆抗体作为治疗后药物的多发性硬化患者的观点
Abdorreza Naser Moghadasi
Abdorreza Naser Moghadasi
What is " chronic" pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment [0.03%]
什么是「慢性」脓疱型银屑病？寻找长期皮下注射斯巴妥利单抗的候选患者
Angelo Valerio Marzano,Carlo Alberto Maronese,Anna Balato et al.
Angelo Valerio Marzano et al.
Review on recommendations on the use of biologic therapy for the management of moderate-severe psoriasis in Saudi Arabia: an expert opinion [0.03%]
沙特阿拉伯关于中重度银屑病生物制剂管理的专家建议综述
Mohammed Fatani,Abdullah Aldugaither,Mufaddal Alaithan et al.
Mohammed Fatani et al.
Introduction: Psoriasis is a chronic inflammatory skin disorder with a significant global burden, impacting patients both physically and psychologically. While its exact etiology remains unclear, genetic predisposition an...
Addressing practical challenges with bispecific antibody therapy in multiple myeloma [0.03%]
双特异性抗体治疗多发性骨髓瘤的实际挑战应对策略分析
Sreeraj Vasudevan,Bhavesh Mohan Lal,Nikhil Vojjala et al.
Sreeraj Vasudevan et al.
Introduction: Bispecific antibodies (bsAbs) have demonstrated impressive standalone effectiveness in relapsed and refractory multiple myeloma, as evidenced by clinical trials and real-world findings. Current clinical stud...
Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome [0.03%]
靶向自身抗体治疗后新冠肺炎综合症和肌痛性脑脊髓炎/慢性疲劳综合征
Felix Wohlrab,Mailam Eltity,Friederike Ufer et al.
Felix Wohlrab et al.
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance [0.03%]
注射用efgartigimod在日本全身型重症肌无力患者中的安全性及有效性：上市后监察的中期分析结果
Hirofumi Teranishi,Koichi Tsuda,Rumiko Kanzaki et al.
Hirofumi Teranishi et al.
Background: Efgartigimod for intravenous infusion (efgartigimod-IV) is approved in Japan for generalized myasthenia gravis (gMG). Post-marketing surveillance was mandated by regulatory authorities to assess the safety and...
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries [0.03%]
低收入及中等收入国家使用生物制剂治疗哮喘的现状及展望
Betül Özdel Öztürk,Sevim Bavbek
Betül Özdel Öztürk